Current Trends in Monoclonal Antibody Development and Manufacturing: Biotechnology: Pharmaceutical Aspects, cartea XI
Editat de Steven J. Shire, Wayne Gombotz, Karoline Bechtold-Peters, James Andyaen Limba Engleză Paperback – 25 feb 2012
Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1230.32 lei 6-8 săpt. | |
Springer – 25 feb 2012 | 1230.32 lei 6-8 săpt. | |
Hardback (1) | 1184.91 lei 6-8 săpt. | |
Springer – 12 noi 2009 | 1184.91 lei 6-8 săpt. |
Preț: 1230.32 lei
Preț vechi: 1500.39 lei
-18% Nou
Puncte Express: 1845
Preț estimativ în valută:
235.47€ • 248.41$ • 196.23£
235.47€ • 248.41$ • 196.23£
Carte tipărită la comandă
Livrare economică 03-17 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781461424918
ISBN-10: 1461424917
Pagini: 368
Ilustrații: XIV, 354 p.
Dimensiuni: 178 x 254 x 19 mm
Greutate: 0.64 kg
Ediția:2010
Editura: Springer
Colecția Springer
Seria Biotechnology: Pharmaceutical Aspects
Locul publicării:New York, NY, United States
ISBN-10: 1461424917
Pagini: 368
Ilustrații: XIV, 354 p.
Dimensiuni: 178 x 254 x 19 mm
Greutate: 0.64 kg
Ediția:2010
Editura: Springer
Colecția Springer
Seria Biotechnology: Pharmaceutical Aspects
Locul publicării:New York, NY, United States
Public țintă
Professional/practitionerCuprins
Design Of Therapeutic MABS.- CDR Repair: A Novel Approach to Antibody Humanization.- Nanobodies, Single-Domain Antigen-Binding Fragments of Camelid Heavy-Chain Antibodies.- Expression and Production of MABS.- GPEx® A Flexible Method for the Rapid Generation of Stable, High Expressing, Antibody Producing Mammalian Cell Lines.- Advancing Our Cell Culture Platform: Incorporating Lessons Learned and New Technologies.- Recovery and Purification.- Addressing Changes Associated with Technology Transfer: A Case Study.- Concepts for Disposables in Biopharmaceutical Manufacture.- Formulation and Delivery.- Formulation and Delivery Issues for Monoclonal Antibody Therapeutics.- Challenges in the Development of High Protein Concentration Formulations.- Protein Immobilization by Crystallization and Precipitation: An Alternative to Lyophilization.- Analytics and Specification Setting for MABS.- Characterizing High Affinity Antigen/Antibody Complexes by Kinetic and Equilibrium Based Methods.- Analytical Characterization of Monoclonal Antibodies: Linking Structure to Function.- Analysis of Irreversible Aggregation, Reversible Self-association and Fragmentation of Monoclonal Antibodies by Analytical Ultracentrifugation.- Biophysical Signatures of Monoclonal Antibodies.- Pharmacokinetics and Immunogenicity.- Impact of Fc Glycosylation on Monoclonal Antibody Effector Functions and Degradation by Proteases.- Immunogenicity Assessment of Antibody Therapeutics.- Armed Antibodies and New Classes of Antibodies.- Production of Monoclonal Antibodies in E. coli.- Recent Advancements in the Use of Antibody Drug Conjugates for Cancer Therapy.- Antibody Radiolabeling.
Caracteristici
Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry and monoclonal antibodies products will become increasingly prevalent over the next decade Provides an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission Includes supplementary material: sn.pub/extras